<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165994</url>
  </required_header>
  <id_info>
    <org_study_id>APX005M-006</org_study_id>
    <nct_id>NCT03165994</nct_id>
  </id_info>
  <brief_title>APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers</brief_title>
  <official_title>A Phase 2 Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apexigen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apexigen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase II trial studies the side effects of CD40 agonistic monoclonal antibody&#xD;
      APX005M (APX005M), chemotherapy, and radiation therapy, and to see how well they work when&#xD;
      given before surgery in treating patients with esophageal cancer or gastroesophageal cancer&#xD;
      that can be removed by surgery. APX005M is intended to stimulate the body's own immune system&#xD;
      so that the immune cells can more effectively invade and destroy the tumor, adding to the&#xD;
      benefits of the chemotherapy and radiation therapy. Drugs used in chemotherapy, such as&#xD;
      carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either&#xD;
      by killing the cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
      Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving&#xD;
      APX005M, chemotherapy, and radiation therapy before surgery may make the tumor smaller and&#xD;
      reduce the amount of normal tissue that needs to be removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the efficacy of this novel combination, as measured by the pathologic complete&#xD;
      response (pCR) rate.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To further characterize the safety and feasibility of combining APX005M with SOC&#xD;
           chemoradiation (external beam radiation in daily fractions, with concurrent weekly&#xD;
           low-dose carboplatin/paclitaxel) in the neoadjuvant setting for patients with resectable&#xD;
           esophageal and GE junction cancers.&#xD;
&#xD;
        2. To assess the efficacy of combining APX005M with SOC chemoradiation as measured by rates&#xD;
           of R0 resection (microscopically negative margins, i.e., no tumor remains following&#xD;
           surgery); and radiographic/metabolic response to neoadjuvant treatment on CT-PET.&#xD;
&#xD;
      Exploratory Objectives:&#xD;
&#xD;
        1. To identify possible predictive molecular or immune-based efficacy biomarkers for this&#xD;
           novel combination.&#xD;
&#xD;
        2. To characterize and assess overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Non-comparative, open-label pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR) rate</measure>
    <time_frame>At time of surgery (at 10-16 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of R0 resection (microscopically negative margins, i.e., no tumor remains following surgery)</measure>
    <time_frame>At time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic stage at time of surgery</measure>
    <time_frame>At time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic/metabolic response to neoadjuvant treatment on Computed Tomography (CT) / CT-Positron Emission Tomography (PET) (CT-PET)</measure>
    <time_frame>Baseline, then at time of surgery, and 3 and 6 months post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>Up to 5 months for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>GastroEsophageal Cancer</condition>
  <arm_group>
    <arm_group_label>APX005M with chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APX005M: 0.3mg/kg dose intravenously over 1 hour, every 3 weeks x 3 doses (weeks 1, 4, and 7). Treatment begins 2 weeks prior to concurrent chemoradiation (chemoRT); continues during weeks 2 and 5 of chemoRT.&#xD;
Daily radiation therapy (RT): 28 fractions (28 days)&#xD;
Chemotherapy: Carboplatin and paclitaxel will be given intravenously over 1 hour, once weekly, for 5 weeks (days 1, 8, 15 22, and 29 of RT). Carboplatin dose will be area under curve (AUC) 2. Paclitaxel dose will be 50mg/m2.&#xD;
Surgical resection of tumor: between weeks 10-16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX005M</intervention_name>
    <description>APX005M intravenous (IV) infusion</description>
    <arm_group_label>APX005M with chemoradiation</arm_group_label>
    <other_name>CD40 Agonistic Monoclonal Antibody)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Radiation therapy, total dose 5040cGy in 180cGy fractions</description>
    <arm_group_label>APX005M with chemoradiation</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel IV infusion</description>
    <arm_group_label>APX005M with chemoradiation</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin IV infusion</description>
    <arm_group_label>APX005M with chemoradiation</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection of tumor</intervention_name>
    <description>Surgical removal of the tumor will occur between weeks 10-16</description>
    <arm_group_label>APX005M with chemoradiation</arm_group_label>
    <other_name>Surgery</other_name>
    <other_name>Operation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years of age&#xD;
&#xD;
          2. Histologically proven squamous cell carcinoma, adenocarcinoma or undifferentiated&#xD;
             carcinoma of the esophagus or GE junction&#xD;
&#xD;
          3. Surgically resectable (T1-3 Nx preferably by endoscopic ultrasound [EUS]). (Excluded:&#xD;
             T1N0 tumors, cervical esophageal location, tumors invading the tracheobronchial tree&#xD;
             or with fistula, distant disease that cannot be included in the radiation field or be&#xD;
             resected at the time of esophagectomy)&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          5. Adequate hematological, renal, and hepatic parameters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any history of or current hematologic malignancy&#xD;
&#xD;
          2. History of a second primary cancer is allowed in the event the cancer is curatively&#xD;
             resected and there is no evidence of recurrence/metastatic disease x 1 year. Subjects&#xD;
             who have a history of cervical or breast carcinoma in situ, localized prostate cancer,&#xD;
             adequately treated basal cell or squamous cell carcinoma of the skin, or superficial&#xD;
             bladder tumors [Ta, Tis &amp; T1] are also allowed.&#xD;
&#xD;
          3. Major surgery within 4 weeks of first dose of investigational product&#xD;
&#xD;
          4. Prior or concurrent treatment with any anticancer agent for the same cancer diagnosis&#xD;
&#xD;
          5. Prior exposure to any immuno-oncology agents, including CD40/PD-1/PD-L1/CTLA-4&#xD;
             inhibitors (if any ambiguity, should be discussed with study principal investigator)&#xD;
&#xD;
          6. History of bone marrow transplantation&#xD;
&#xD;
          7. History of autoimmune disorders with the exception of vitiligo or autoimmune thyroid&#xD;
             disorders&#xD;
&#xD;
          8. Chronic steroid dependency (prednisone equivalent &gt; 10 mg/day). Any steroid use should&#xD;
             be discontinued at least 2 weeks prior to initiation of study treatment.&#xD;
&#xD;
          9. Congestive heart failure (New York Heart Association Class III to IV), symptomatic&#xD;
             ischemia, conduction abnormalities uncontrolled by conventional intervention, or&#xD;
             myocardial infarction within 6 months before first dose&#xD;
&#xD;
         10. Known human immunodeficiency virus (HIV) infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>650-931-6236</phone>
    <email>info@apexigen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron J Scott, MD</last_name>
      <email>ajscott@arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Chao, MD</last_name>
      <email>jchao@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew H Ko, MD</last_name>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital (MGUH)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Noel, MD</last_name>
      <email>marcus.s.noel@gunet.georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul E Oberstein, MD</last_name>
      <email>paul.oberstein@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Autumn McRee, MD</last_name>
      <email>autumn_mcree@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caio Rocha Lima, MD</last_name>
      <email>crochali@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davendra Sohal, MD</last_name>
      <email>sohalda@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Crow, MD</last_name>
      <email>mary.crow@renovatioclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veena Shankaran, MD</last_name>
      <email>vshank@u.washington.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophagus</keyword>
  <keyword>gastroesophageal (GE) junction</keyword>
  <keyword>T1-3N0-1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

